Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Cash & Equivalents (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Cash & Equivalents for 6 consecutive years, with $152.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 14.71% to $152.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $152.4 million, a 14.71% decrease, with the full-year FY2025 number at $152.4 million, down 14.71% from a year prior.
  • Cash & Equivalents was $152.4 million for Q4 2025 at TScan Therapeutics, down from $169.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $242.2 million in Q2 2024 to a low of $95.6 million in Q1 2023.
  • A 5-year average of $150.5 million and a median of $140.8 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: soared 363.93% in 2021, then plummeted 32.11% in 2023.
  • TScan Therapeutics' Cash & Equivalents stood at $161.4 million in 2021, then fell by 25.64% to $120.0 million in 2022, then grew by 11.11% to $133.4 million in 2023, then skyrocketed by 33.99% to $178.7 million in 2024, then decreased by 14.71% to $152.4 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Cash & Equivalents are $152.4 million (Q4 2025), $169.5 million (Q3 2025), and $154.1 million (Q1 2025).